How to invest in Anthropic pre-IPO as a retail investor
Are you a retail investor wanting Anthropic exposure before Wall Street has a few indirect ways in, while the company stays private? Well, welcome!
As Cryptopolitan recently reported, Anthropic ended July with annualized revenue above $65 billion, which is ahead of expectations. The Claude creator filed an early S-1 in June, according to CNBC, and at the scale now being discussed, it could become the largest market debut ever for a foundation-model company.
The challenging thing for ordinary investors is later-stage private funding rounds are normally dominated by venture capitalists, institutional investors, company founders, employees, and wealthy individuals.
One route is through funds that currently hold Anthropic in their portfolio, since that would mean that you aren’t directly investing in Anthropic, but rather in a portion of it held by the fund. According to the Financial Times, there were reports that investors believed trading could begin as early as October. This came after reports that the firm was worth up to $2 trillion.
Listed funds already let retail investors get a small piece of Anthropic before any IPO
One place to start is exchange-traded funds already holding private Anthropic shares. The iShares AI Innovation & Tech Active ETF (BAI) has a position.
So do the T. Rowe Price Technology ETF (TTEQ) and the KraneShares Public-Private AI & Technology ETF (AGIX). Both BAI and TTEQ invest privately in OpenAI, which is one of Anthropic’s main foundation model rivals. This means that buying either ETF will provide you access to two private AI companies among others. This is not a way of investing in Anthropic.
Fred Alger Management provides three additional ways for retail investors to do this via publicly listed ETFs. Anthropic is included in the Alger 35 ETF (ATFV), Alger AI Enablers & Adopters ETF (ALAI), and Alger Concentrated Equity ETF (CNEQ).
Among the ETFs mentioned, the CNEQ has the largest Anthropic position. Even there, Anthropic accounts for less than 4% of the fund’s composition. Investing $1,000 in CNEQ does not mean investing $1,000 in Anthropic. Part is invested in Anthropic while the remaining in other assets.
Cathie Wood gives investors another option through ARK Invest’s ARK Venture Fund (ARKVX). Cathie’s fund is not a normal ETF. ARKVX is a closed-end fund with a minimum investment of $500 and a net expense ratio of 2.9%. Though the fund is also semi-liquid, selling the whole position whenever you want is not exactly always be possible.
Fundrise cuts the minimum while Anthropic’s private share estimate sits above $692
A cheaper entry point comes through the Fundrise Innovation Fund (VCX). Fundrise says the fund owns Anthropic alongside other private startups. Investors can start with just $10.
VCX continues to be a closed-end fund, hence, the reduced minimum will not eliminate its liquidity constraints. Morningstar (NASDAQ: MORN) has also provided observations that potential investors could want to take into consideration regarding the analysis of the fund.
In addition, there is a private market valuation that investors could consider in evaluating Anthropic since the company is not listed. According to Nasdaq Private Market, the value of Anthropic’s share stands at $692.39 as of August 11, 2026. The valuation is called the NPM price.
NPM builds the figure from private transactions, public valuation information, and its own proprietary data. Investors who pay for NPM Data and Intelligence can see more details on the current estimate and the factors affecting it.
Anthropic is also meeting with possible investors prior to figuring out how and when to proceed further. Chief Financial Officer Krishna Rao is spearheading these early meetings.
Krishna has talked about the suite of Claude models, how Anthropic created Claude Code, the company’s position in the enterprise AI market, the company’s management team, and number of product launches.
The choice comes down to how much Anthropic each vehicle owns, what it charges, how easily you can get your money back if you do decide to invest, and how much of your portfolio is tied to other assets.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Voices of doubt arise, Moderna CEO reassures the market: Personalized cancer vaccines will cover more types of cancer
Moderna's CEO is highly confident about the prospects of the personalized mRNA cancer vaccine intismeran autogene, stating that it will play a role in more cancers beyond melanoma and drawing parallels with Merck's blockbuster drug Keytruda. Jefferies warns that cross-indication replication is still inconclusive; Citi maintains a "sell" rating, pointing out that commercial application remains limited, with critical issues such as patient suitability, manufacturing, and overall survival data yet to be addressed.
Morgan Stanley Declares U.S. Stock Market Correction Nears End! Maintains Year-End S&P 8000 Target, Identifies Three Major Rebound Catalysts
As Morgan Stanley remains bullish on the stock market, recent market trends have precisely demonstrated the strong rebound momentum of tech stocks dominated by the semiconductor sector. The Philadelphia Semiconductor Index rose by 0.44% on October 23rd and further increased by 2.82% on the 26th.
Eight Highlights of Anthropic IPO Prospectus: Astonishing Growth, but Risks are Obvious
The Anthropic prospectus reveals several highlights: a large-scale enterprise customer base with over 1,900 customers generating more than one million dollars in revenue; as of June 2026, revenue has increased by 1,368% year over year, far surpassing the growth rate of computing costs; positive operating cash flow; and all seven co-founders remain with the company. The company also acknowledges risks, including concentrated supply from TSMC and potential memory chip shortages as significant concerns. October ARR data will be additionally disclosed in a revised version of the document.
Selling Chips, Leasing, Providing Residual Value Support: Broadcom (AVGO.US) Teams Up with Wall Street's Four Giants to Raise $63 Billion to "Inject Funds" for Anthropic's Chip Procurement
Broadcom has reached a $63 billion deal with Bank of America, Blackstone Group, Citigroup, and Morgan Stanley to provide funding for the purchase of chips for AI model developer Anthropic PBC. The transaction is conducted through a newly established special purpose company, which has secured financial commitments from these firms to purchase Broadcom chips and lease them to Anthropic.
Crypto prices
More
